Skip to main content
Clinical Trials/NCT02021760
NCT02021760
Completed
Not Applicable

Reduction in Infarct Size by Remote Per-postconditioning in Patients With ST-elevation Myocardial Infarction in Stockholm (RECOND)

John Pernow3 sites in 1 country120 target enrollmentMay 2013

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Coronary Artery Disease
Sponsor
John Pernow
Enrollment
120
Locations
3
Primary Endpoint
Myocardial infarct size expressed as a percentage of the myocardium at risk determined by Cardiac Magnetic Resonance
Status
Completed
Last Updated
10 years ago

Overview

Brief Summary

  • Trial objective: To test the hypothesis that remote per-postconditioning in connection with primary PCI will reduce myocardial infarct size patients with STEMI.
  • Trial Design: Placebo controlled randomized study with parallel groups
  • Primary Endpoint: Myocardial infarct size expressed as a percentage of the myocardium at risk determined by Cardiac Magnetic Resonance (CMR) day 4-7
  • Efficacy Parameters: Myocardial infarct size expressed as a percentage to the myocardium at risk determined by CMR at 6 months.
  • Global left ventricular function determined by left ventricular ejection fraction determined by CMR.
  • Microvascular obstruction determined by CMR day 4-7. Quantified ECV (extracellular volume) in left ventricular as myocardium at risk day 4-7 and remodelling parameters day 180.
  • Safety Parameters: Major adverse cardiovascular events.

Detailed Description

See above. 3 patients left to include.

Registry
clinicaltrials.gov
Start Date
May 2013
End Date
November 2015
Last Updated
10 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
John Pernow
Responsible Party
Sponsor Investigator
Principal Investigator

John Pernow

Professor

Karolinska Institutet

Eligibility Criteria

Inclusion Criteria

  • Patient planned for primary PCI.
  • Chest pain indicating myocardial ischemia with a duration \>30 minutes and \< 6 hours prior to randomization.
  • ST elevations \>0.1 mV (\>0.2 mV in V2-V3) in \> two contiguous leads in V1-V
  • Informed consent.

Exclusion Criteria

  • Previous myocardial infarction based on medical history or Q-wave on ECG in other area
  • Left Bundle Branch Block on ECG.
  • Previous CABG
  • Cardiac arrest
  • Any contraindication for CMR.
  • Clinical symptoms of claudication
  • Treatment with glibenclamide or cyclosporine on admission.
  • Any condition that may interfere with the possibility for the patient to comply with or complete the study protocol.

Outcomes

Primary Outcomes

Myocardial infarct size expressed as a percentage of the myocardium at risk determined by Cardiac Magnetic Resonance

Time Frame: 4-7 days following index event

Secondary Outcomes

  • Myocardial infarct size expressed as a percentage to the myocardium at risk determined by Cardiac Magnetic Resonance(6 months following index event)

Study Sites (3)

Loading locations...

Similar Trials